MetaCap

Aurinia Pharmaceuticals (AUPH) vs Septerna (SEPN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Septerna (SEPN) has outperformed Aurinia Pharmaceuticals (AUPH) over the past year, gaining 51.1% versus a loss of 6.3%. Aurinia Pharmaceuticals is the larger company by market cap ($1.97 billion vs $1.84 billion), about 1.1 times the size, while Septerna is growing revenue faster (+4174.5% vs +20.4%). Aurinia Pharmaceuticals converts more of its revenue into profit, with a net margin of 101.5% versus -106.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AUPH-6.25%SEPN+51.06%
+111%+47%-17%
Nov 21, 20251 yearNov 20, 2026
AUPH+108.51%SEPN+80.42%
+155%+35%-85%
Oct 21, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AUPH versus SEPN key metrics
MetricAUPHSEPN
Share price$14.70$38.61
Market cap$1.97B$1.84B
1-day change-1.28%-1.51%
YTD return-7.84%+38.49%
1-year return-6.25%+51.06%
5-year return-23.95%—
P/E ratio (TTM)6.45—
Forward P/E12.67—
EPS (TTM)$2.28$-1.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$283.06M$45.95M
Revenue growth (YoY)+20.38%+4174.51%
Net income (latest FY)$287.20M$-48.88M
Gross margin88.46%—
Operating margin37.06%-148.63%
Net margin101.47%-106.37%
52-week high$19.25$53.34
52-week low$13.52$22.78
Distance from 52-week high-23.64%-27.62%
Analyst consensusbuystrong_buy
Avg. price target upside+25.85%+53.38%
Average volume858.74K383.96K
Shares outstanding134.00M47.55M
Employees128134
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SEPN has outperformed AUPH by 57.3 percentage points over the past year.
  • Aurinia Pharmaceuticals is more profitable, keeping 101.5 cents of every revenue dollar as net income versus -106.4 cents for Septerna.
  • Septerna grew revenue faster in its latest fiscal year (+4174.51% vs +20.38%).

About Aurinia Pharmaceuticals

AUPH stock →

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

About Septerna

SEPN stock →

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 134 employees

AUPH vs SEPN FAQ

Which is bigger, Aurinia Pharmaceuticals or Septerna?

Aurinia Pharmaceuticals (AUPH) is larger, with a market capitalization of $1.97B compared with $1.84B for Septerna (SEPN).

Which stock has performed better over the past year, AUPH or SEPN?

SEPN returned +51.06% over the past 12 months, compared with -6.25% for AUPH (price return, excluding dividends). Past performance does not predict future results.

Are Aurinia Pharmaceuticals and Septerna in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons